BioSpace News Archive

At a dedication of the new Jeffrey Leiden Center for Cell and Genetic Therapies in Boston’s Seaport, Vertex Pharmaceuticals Incorporated announced plans to build another 344,000 square foot facility in the Seaport to support the company’s continued rapid growth, in particular the expansion of its cell and genetic therapies programs.

AviadoBio, a pioneering, pre-clinical stage gene therapy company focused on developing and delivering transformative medicines for people with neurodegenerative disorders, today presents preclinical data on its investigational, one-time, adeno-associated virus (AAV) gene therapy, AVB-101 (AVB-PGRN), in an oral presentation at the American Society of Gene & Cell Therapy annual meeting (ASGCT 2022).

Bio-Path Holdings, Inc. announced its financial results for the first quarter ended March 31, 2022 and provided an update on recent corporate developments.

Kronos Bio, Inc., a company dedicated to transforming the lives of those affected by cancer and other serious diseases, announced participation in the H.C. Wainwright Global Investment Conference.

TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of T-cell receptor engineered T cell therapies for the treatment of patients with cancer, announced that management will participate in a virtual fireside chat at the H.C. Wainwright Global Investment Conference that will be available for viewing on Tuesday, May 24, 2022, at 7:00 a.m. ET.

OraSure Technologies, Inc. announced that its InteliSwab® COVID-19 rapid tests detect the Omicron BA.2, BA.2.12.1, BA.3 and BA.5 subvariants with similar levels of detection to the original SARS-CoV-2 strain and other previous variants of concern, including Delta, Alpha, Beta, Gamma and Omicron BA.1.

A new progestin-only contraceptive pill is now available to Canadians from Duchesnay Inc., a pharmaceutical company specializing in women’s health and part of the Duchesnay Pharmaceutical Group headquartered in Blainville, Quebec.

Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, today provided an update on recent progress achieved in its ongoing pivotal Phase 3 InnovAATe clinical trial evaluating the safety and efficacy of the Company’s proprietary inhaled Alpha-1 Antitrypsin (AAT) therapy for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).

Calithera Biosciences, Inc. announced that Susan Molineaux, Ph.D., the company’s founder, president and chief executive officer, will present at the H.C. Wainwright Global Investment Conference, being held May 23-25 both virtually and in Miami, FL.

ProMIS Neurosciences, Inc. announced its participation at the Neuro4D International Conference, held at the Atrium Hotel, Mainz, Germany, May 16-17th.